A POST MARKETING SURVEILLANCE STUDY TO EVALUATE THE SAFETY AND EFFICACY of PANKAJAKASTHURI BREATHE EAZY GRANULES AND SYRUP
- Conditions
- Health Condition 1: J40-J47- Chronic lower respiratory diseasesHealth Condition 2: J20-J22- Other acute lower respiratory infectionsHealth Condition 3: J96-J99- Other diseases of the respiratory systemHealth Condition 4: J30-J39- Other diseases of upper respiratory tract
- Registration Number
- CTRI/2021/07/034636
- Lead Sponsor
- Pankajakasthuri Herbals India Pvt Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
1.Age: 19 Years and above
2.Subjects who have participated in the retrospective cross-sectional PMS of Breathe eazy granules and syrup.
3.Patients willing to take Breathe Eazy granules and syrup in a dose of 1 table spoon twice daily after food continuously for a minimum period of 3 months.
4.Subjects who have started taking Breathe Eazy granules and syrup at least for last 3 months.
5.Subjects willing to enroll in study by signing Informed consent.
6.Subjects presenting with Allergic bronchitis, Allergic rhinitis, COPD, Sinusitis, Eosinophilia and other Respiratory tract infections.
1.Subjects who have not taken Breathe Eazy granules and syrup in the prescribed dose and duration.
2.Diagnosed patients of Diabetes Mellitus (DM)
Study & Design
- Study Type
- PMS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Any marked change in safety parameters measured during the administration of the product. <br/ ><br>â?¢Reporting the effectiveness of this product in the management of Allergic bronchitis, Allergic rhinitis, COPD, Sinusitis, Eosinophilia and other Respiratory tract infections and associated complaints. <br/ ><br>Timepoint: oth-baseline1st-first response to questionnaire and 2nd-response at the end of the study
- Secondary Outcome Measures
Name Time Method Additional therapeutic advantages of the productTimepoint: oth-baseline1st-first response to questionnaire and 2nd-response at the end of the study